Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 30, 2026International Journal of Innovative Technologies in Social ScienceOpen Access

Available evidence suggests that GLP-1-based therapies offer clinically meaningful benefits, particularly in patients with obesity, type 2 diabetes, HFpEF, and CKD, improving symptoms, physical limitations, exercise capacity, body weight, and reducing clinically important kidney outcomes.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Heart failure and chronic kidney disease frequently coexist within the cardiovascular-kidney-metabolic continuum, creating a need to summarize evidence on GLP-1-based therapies across these overlapping conditions.

Design

Narrative review informed by general scoping review principles

Authors

DSDaria SztefkaAJAgata JaunichKSKatarzyna Szlachetka

Discussion

Loading...

Member takes

Overview

Supports integrated CKM management for coexisting HF and CKD; leaves open optimal therapeutic strategies.

Structured PICO

P
Population
Patients with heart failure (HF) and chronic kidney disease (CKD), particularly those with obesity, type 2 diabetes, and HF with preserved ejection fraction (HFpEF).
I
Intervention
GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) and technology-enabled care.

GLP-1 receptor agonists are emerging as foundational therapies in the cardiovascular-kidney-metabolic (CKM) framework, offering symptom relief, cardiovascular risk reduction, and kidney protection in patients with HFpEF and CKD.

Limitations

  • Not designed as a formal systematic review or meta-analysis
  • Intentionally prioritizes coherence and translational usefulness over exhaustive enumeration of every available publication

Cite This Study

Sztefka et al. (2026) studied this question.

synapsesocial.com/papers/6a836a2d474150bc0b1823a8https://doi.org/10.31435/ijitss.1(49).2026.5402
View Full Paper
Ask AI
Bookmark
Share